Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy-Reference-Cited by-同舟云学术

Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy

Published:2019-10 Issue: Volume:136 Page:30-36
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Choe Eun-Ah^ORCID,Cha Yoon Jin^ORCID,Kim Jae-Hwan,Pyo Kyoung Ho,Hong Min Hee^ORCID,Park Seong Yong,Shim Hyo Sup^ORCID,Jung Inkyung,Lee Chang Young,Cho Byoung Chul^ORCID,Kim Hye Ryun^ORCID

Funder

Bio & Medical Technology Development Program of the National Research Foundation

Ministry of Science and ICT

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference43 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J. Clin.,2016

2. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008

3. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Crino;Ann. Oncol.,2010

4. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Postmus;Ann. Oncol.,2017

5. Survival after pneumonectomy for stage III non-small cell lung cancer;Saha;Oman Med. J.,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study;Clinical Lung Cancer;2024-07

2. The pathogenic response of cytotoxic T‑lymphocytes, a common therapeutic target for cancer, has a direct impact on treatment outcomes (Review);Oncology Reports;2024-06-17

3. Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC;Journal for ImmunoTherapy of Cancer;2024-04

4. Apatinib Plus Toripalimab (Anti-PD1 Therapy) as Second-Line Therapy in Patients With Advanced Gastric or Esophagogastric Junction Cancer: Results From a Randomized, Open-Label Phase II Study;The Oncologist;2024-02-16

5. First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET;Journal for ImmunoTherapy of Cancer;2024-02